Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(8%)
Terminated
1(8%)

Phase Distribution

Ph phase_2
7
58%
Ph phase_1
5
42%

Phase Distribution

5

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
7(58.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(5)
Terminated(1)
Other(6)

Detailed Status

unknown6
Not yet recruiting4
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (41.7%)
Phase 27 (58.3%)

Trials by Status

recruiting18%
terminated18%
unknown650%
not_yet_recruiting433%

Recent Activity

1 active trials
Showing 5 of 12
recruitingphase_2

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

NCT07183865
not_yet_recruitingphase_2

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

NCT06989671
not_yet_recruitingphase_1

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

NCT06682611
terminatedphase_2

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

NCT05009953
not_yet_recruitingphase_1

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

NCT06136988
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07183865Phase 2

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Recruiting
NCT06989671Phase 2

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not Yet Recruiting
NCT06682611Phase 1

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Not Yet Recruiting
NCT05009953Phase 2

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Terminated
NCT06136988Phase 1

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Not Yet Recruiting
NCT06132217Phase 1

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Not Yet Recruiting
NCT06089330Phase 2

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown
NCT05508659Phase 1

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Unknown
NCT04886700Phase 2

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Unknown
NCT05068141Phase 2

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Unknown
NCT04983550Phase 2

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Unknown
NCT03852823Phase 1

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12